GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » FCF Yield %

IVVD (Invivyd) FCF Yield % : -270.62 (As of Apr. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Invivyd FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Invivyd's Trailing 12-Month Free Cash Flow is $-170.63 Mil, and Market Cap is $63.05 Mil. Therefore, Invivyd's FCF Yield % for today is -270.62%.

The historical rank and industry rank for Invivyd's FCF Yield % or its related term are showing as below:

IVVD' s FCF Yield % Range Over the Past 10 Years
Min: -398.42   Med: -168.01   Max: -69.86
Current: -270.62


During the past 5 years, the highest FCF Yield % of Invivyd was -69.86%. The lowest was -398.42%. And the median was -168.01%.

IVVD's FCF Yield % is ranked worse than
92.85% of 1497 companies
in the Biotechnology industry
Industry Median: -15.53 vs IVVD: -270.62

Invivyd's FCF Margin % for the quarter that ended in Dec. 2024 was -272.11%.


Invivyd FCF Yield % Historical Data

The historical data trend for Invivyd's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd FCF Yield % Chart

Invivyd Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
- -22.98 -135.54 -40.04 -321.35

Invivyd Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.59 -38.05 -126.65 -134.67 -283.28

Competitive Comparison of Invivyd's FCF Yield %

For the Biotechnology subindustry, Invivyd's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invivyd's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Invivyd's FCF Yield % falls into.


;
;

Invivyd FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Invivyd's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-170.631 / 53.0988885
=-321.35%

Invivyd's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-37.605 * 4 / 53.0988885
=-283.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invivyd FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Invivyd FCF Yield % Related Terms

Thank you for viewing the detailed overview of Invivyd's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Invivyd Business Description

Traded in Other Exchanges
N/A
Address
1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Executives
Terrance Mcguire director, other: See Remarks C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Adimab, Llc 10 percent owner, other: See Remarks 7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke officer: Chief Financial Officer C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter director 1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii officer: Chief Scientific Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price officer: Chief Tech. and Manuf. Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler officer: COO & CCO 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora officer: Chief Tech and Manuf Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt officer: Chief Medical Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen officer: Chief Legal Officer, Secretary 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom director 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll officer: Interim CFO
David Hering director, officer: Chief Executive Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia director, other: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp other: See Remarks 700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902